Press Release
Press Release
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
According to a new report by EMR titled, ‘Global Alprazolam Powder Market Report and Forecast 2021-2026’, the global market for alprazolam powder is expected to grow at a CAGR of 3.6% in the forecast period of 2021-2026.
The alprazolam powder industry is being driven by the rising anxiety disorders across the globe, with alprazolam being the primary ingredient in leading anti-anxiety drugs. According to the World Health Organisation, mental illnesses account for nearly 15% of the overall disease conditions globally, with over 300 million people suffering from anxiety disorders.
In the United States, nearly 1 in 5 adults have been estimated to suffer from anxiety disorders, with generalised anxiety disorder rates increasing among the teenage population of the country. Due to the significant proportion of the population relying on alprazolam-based anxiety medications in the United States, the alprazolam powder industry in the country is witnessing a robust growth. The Asia Pacific is also expected to emerge as a significant market for alprazolam powder due to the rising pharmaceutical industry and the growing de-stigmatisation of mental health-related disorders, which is leading to a wider range of people seeking treatment. The rising mental-health awareness campaigns and programmes, like Swach Mansikta Abhiyan and accredited social health activist (ASHA) programme initiated by the Government of India, are expected to further aid the market growth in the Asia Pacific.
Pfizer Inc. (NYSE: PFE) is one of the leading players in the alprazolam powder industry. The company is the manufacturer of Xanax, which has almost become synonymous with alprazolam-based anti-anxiety tablets. Xanax became a part of Pfizer’s portfolio upon its acquisition of Pharmacia, which had earlier bought Upjohn, the company which initially started commercially producing Xanax. With benzodiazepines like Xanax still being one of the most commonly prescribed anti-anxiety drugs, Pfizer is expected to remain of the most significant players in the alprazolam powder industry.
Market Analysis by Type, Application, End Use, and Region:
Key Findings of the Report:
Key Offerings of the Report:
The major players in the global alprazolam powder market are Pfizer Inc., Terrace Pharmaceuticals, and Sandoz AG, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.